Trevena, Inc. (TRVN)

NASDAQ: TRVN · IEX Real-Time Price · USD
3.45
0.00 (-0.14%)
At close: Dec 1, 2022 4:00 PM
3.35
-0.10 (-2.90%)
After-hours: Dec 1, 2022 6:26 PM EST
-0.14%
Market Cap 24.01M
Revenue (ttm) -419,000
Net Income (ttm) -60.62M
Shares Out 6.83M
EPS (ttm) -0.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Nov 10, 2022
Volume 17,240
Open 3.44
Previous Close 3.46
Day's Range 3.39 - 3.5
52-Week Range 2.38 - 19
Beta 1.86
Analysts Buy
Price Target 1.87 (-45.8%)
Earnings Date Nov 9, 2022

About TRVN

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agon... [Read more]

Industry Biotechnology
IPO Date Jan 31, 2014
CEO Carrie Bourdow
Employees 43
Stock Exchange NASDAQ
Ticker Symbol TRVN
Full Company Profile

Financial Performance

In 2021, Trevena's revenue was $567,000, a decrease of -81.52% compared to the previous year's $3.07 million. Losses were -$51.59 million, 75.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for TRVN stock is "Buy." The 12-month stock price forecast is 1.87, which is a decrease of -45.80% from the latest price.

Price Target
$1.87
(-45.80% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Trevena Regains Compliance with Nasdaq Listing Requirements

CHESTERBROOK, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centr...

2 days ago - GlobeNewsWire

Trevena, Inc. Announces $8.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CHESTERBROOK, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medi...

2 weeks ago - GlobeNewsWire

Trevena Announces Reverse Stock Split

CHESTERBROOK, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centr...

3 weeks ago - GlobeNewsWire

Trevena (TRVN) Reports Q3 Loss, Misses Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of 0% and 203.06%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator

TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia

3 weeks ago - GlobeNewsWire

Trevena Reports Third Quarter 2022 Results and Provides Business Update

OLINVYK commercialization progresses with Vizient contract and receipt of CMS outpatient pass-through reimbursement

3 weeks ago - GlobeNewsWire

Trevena to Release Third Quarter 2022 Financial Results on November 9, 2022

Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET

3 weeks ago - GlobeNewsWire

Trevena Announces OLINVYK Poster Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

OLINVYK study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects

1 month ago - GlobeNewsWire

Trevena to Participate at the H.C. Wainwright Annual Global Investment Conference

CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centr...

2 months ago - GlobeNewsWire

What Makes Trevena (TRVN) a New Buy Stock

Trevena (TRVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago - Zacks Investment Research

Trevena (TRVN) Reports Q2 Loss, Lags Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of 18.18% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Trevena Reports Second Quarter 2022 Results and Provides Business Update

OLINVYK post-approval strategy advances with positive topline cognitive function data and continued enrollment in VOLITION clinical outcomes study

3 months ago - GlobeNewsWire

Trevena to Release Second Quarter 2022 Financial Results on August 11, 2022

Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET

3 months ago - GlobeNewsWire

Trevena, Inc. Announces Closing of Registered Direct Offering of Preferred Stock

CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medi...

4 months ago - GlobeNewsWire

Trevena, Inc. Announces Registered Direct Offering of Preferred Stock

CHESTERBROOK, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) ("Trevena" or the "Company"), a biopharmaceutical company focused on the development and commercialization of novel medi...

4 months ago - GlobeNewsWire

Trevena Announces Positive Topline OLINVYK Cognitive Function Data and Provides General Business Update

OLINVYK demonstrated statistically significant reduced impact on neurocognitive functioning vs IV morphine on primary endpoint

4 months ago - GlobeNewsWire

Trevena Announces the Publication of an Expert Review on the Clinical Profile of OLINVYK® in Post-Operative Care

CHESTERBROOK, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centr...

5 months ago - GlobeNewsWire

Trevena to Participate at the JMP Securities Life Sciences Conference

CHESTERBROOK, Pa., June 10, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centr...

5 months ago - GlobeNewsWire

Trevena to Present at the H.C. Wainwright Global Investment Conference

CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centra...

6 months ago - GlobeNewsWire

Trevena (TRVN) Reports Q1 Loss, Lags Revenue Estimates

Trevena (TRVN) delivered earnings and revenue surprises of -11.11% and 96.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Trevena Reports First Quarter 2022 Results and Provides Business Update

OLINVYK refocused commercial strategy initiated mid-Q1

6 months ago - GlobeNewsWire

Trevena to Release First Quarter 2022 Financial Results on May 11, 2022

Company to host a Conference Call & Webcast at 8:00 a.m. ET Company to host a Conference Call & Webcast at 8:00 a.m. ET

6 months ago - GlobeNewsWire

Analysts Estimate Trevena (TRVN) to Report a Decline in Earnings: What to Look Out for

Trevena (TRVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Trevena Announces Results from Respiratory Physiology Study of Head-to-Head Comparison of OLINVYK® and IV Morphine in...

OLINVYK showed a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects

7 months ago - GlobeNewsWire

Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financi...

CHESTERBROOK, Pa., April 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with cent...

7 months ago - GlobeNewsWire